ArticleFrontiers in pharmacology2025
Colistin sulfate versus polymyxin B for the treatment of infections caused by carbapenem-resistant
Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Comparative efficacy and safety of colistin sulfate versus polymyxin B in critically ill patients with carbapenem-resistant gram-negative infections: a pilot inverse probability of treatment weighting-based retrospective cohort study.BMC infectious diseases · 2026Article
- Comparative Effectiveness of Colistin Sodium versus Polymyxin B Sulfate Against CR-GNB: A Retrospective Cohort Study.Infection and drug resistance · 2026Article
- Optimizing Polymyxin B Therapy in Critical Care: Pharmacokinetic Insights and Clinical Outcomes in a Retrospective Cohort Study.Infectious diseases and therapy · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Polymyxins are the last line of defense against carbapenem-resistant Gram-negative bacilli infections. However, the efficacy of polymyxins against the independent risk factor of bacterial species is unknown. We aimed to compare the efficacy and safety of colistin sulfate (CS) and polymyxin B (PMB) for carbapenem-resistant Methods: We carried out a retrospective multicenter study that included patients with CRAB infections at three tertiary hospitals in Guizhou province, China, from 1 Jan 2020 to 30 Jun 2024. Patients were grouped into the CS group and PMB group. The main outcomes were all-cause 28-day mortality and clinical failure rate. The secondary outcomes included the microbiological cure rate, duration of CS or PMB treatment, and length of hospital stay. Safety was evaluated based on the rates of adverse drug reactions. Results: A total of 140 patients were included, with 58 patients in the CS group and 82 patients in the PMB group. All-cause 28-day mortality was 32.8% in the CS group and 37.8% in the PMB group (adjusted HR = 0.73, 95% CI 0.38-1.37, Conclusion: Our results suggest that CS is similarly effective to PMB for CRAB infections but it is associated with fewer safety concerns than PMB. This clinical research provides significant information on the efficacy and safety of CS and PMB for CRAB infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.